373 related articles for article (PubMed ID: 17286767)
21. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
22. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
23. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
Gouw SC; van den Berg HM
Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
26. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
27. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
28. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
[TBL] [Abstract][Full Text] [Related]
29. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
31. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of inhibitors in mild/moderate haemophilia A.
Peerlinck K; Jacquemin M
Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
34. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
[TBL] [Abstract][Full Text] [Related]
35. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
38. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
39. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
Peerlinck K; Hermans C
Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
